These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 29114041)

  • 1. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
    Seitz-Polski B; Debiec H; Rousseau A; Dahan K; Zaghrini C; Payré C; Esnault VLM; Lambeau G; Ronco P
    J Am Soc Nephrol; 2018 Feb; 29(2):401-408. PubMed ID: 29114041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Relevance of Domain-Specific Phospholipase A
    Reinhard L; Zahner G; Menzel S; Koch-Nolte F; Stahl RAK; Hoxha E
    J Am Soc Nephrol; 2020 Jan; 31(1):197-207. PubMed ID: 31843985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.
    Seitz-Polski B; Dolla G; Payré C; Girard CA; Polidori J; Zorzi K; Birgy-Barelli E; Jullien P; Courivaud C; Krummel T; Benzaken S; Bernard G; Burtey S; Mariat C; Esnault VL; Lambeau G
    J Am Soc Nephrol; 2016 May; 27(5):1517-33. PubMed ID: 26567246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.
    Ghiggeri GM; Seitz-Polski B; Justino J; Zaghrini C; Payré C; Brglez V; Dolla G; Sinico A; Scolari F; Vaglio A; Prunotto M; Candiano G; Radice A; Bruschi M; Lambeau G;
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1762-1776. PubMed ID: 33257410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation.
    Lateb M; Ouahmi H; Payré C; Brglez V; Zorzi K; Dolla G; Zaidan M; Boyer-Suavet S; Knebelmann B; Crépin T; Courivaud C; Jourde-Chiche N; Esnault V; Lambeau G; Seitz-Polski B
    J Immunol Res; 2019; 2019():1324804. PubMed ID: 32083137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
    Seitz-Polski B; Dahan K; Debiec H; Rousseau A; Andreani M; Zaghrini C; Ticchioni M; Rosenthal A; Benzaken S; Bernard G; Lambeau G; Ronco P; Esnault VLM
    Clin J Am Soc Nephrol; 2019 Aug; 14(8):1173-1182. PubMed ID: 31340979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy.
    Mahmud M; Pinnschmidt HO; Reinhard L; Harendza S; Wiech T; Stahl RAK; Hoxha E
    PLoS One; 2019; 14(9):e0221293. PubMed ID: 31498806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
    Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
    Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial.
    Brglez V; Boyer-Suavet S; Zorzi K; Fernandez C; Fontas E; Esnault V; Seitz-Polski B
    Front Med (Lausanne); 2020; 7():412. PubMed ID: 32903623
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Membranous nephropathy: Pathophysiology and natural history].
    Seitz-Polski B; Lambeau G; Esnault V
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S75-S81. PubMed ID: 28577747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update membranous nephropathy].
    Hoxha E; Huber TB
    Dtsch Med Wochenschr; 2020 Oct; 145(20):1481-1485. PubMed ID: 33022730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.
    Seitz-Polski B; Payré C; Ambrosetti D; Albano L; Cassuto-Viguier E; Berguignat M; Jeribi A; Thouret MC; Bernard G; Benzaken S; Lambeau G; Esnault VL
    Nephrol Dial Transplant; 2014 Dec; 29(12):2334-42. PubMed ID: 25063424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
    Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
    [No Abstract]   [Full Text] [Related]  

  • 19. Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.
    Seitz-Polski B; Dolla G; Payré C; Tomas NM; Lochouarn M; Jeammet L; Mariat C; Krummel T; Burtey S; Courivaud C; Schlumberger W; Zorzi K; Benzaken S; Bernard G; Esnault VL; Lambeau G
    Biochimie; 2015 Nov; 118():104-15. PubMed ID: 26296473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.